Study on protective effect of shenfu injection on cardiac function of patients undergoing valve replacement.
- Author:
Hui DONG
1
;
Li-ze XIONG
;
Min CHEN
Author Information
- Publication Type:Clinical Trial
- MeSH: Adolescent; Adult; Aortic Valve Insufficiency; drug therapy; physiopathology; surgery; Cardiopulmonary Bypass; Dopamine; therapeutic use; Drug Therapy, Combination; Drugs, Chinese Herbal; therapeutic use; Female; Heart Valve Prosthesis Implantation; Humans; Infusions, Intravenous; Male; Middle Aged; Mitral Valve Insufficiency; drug therapy; physiopathology; surgery; Nitroprusside; therapeutic use; Phytotherapy; Postoperative Period; Rheumatic Heart Disease; drug therapy; physiopathology; surgery
- From: Chinese Journal of Integrated Traditional and Western Medicine 2004;24(1):32-35
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the protective effect of Shenfu injection (SFI) on cardiac function of patients undergoing valve replacement operation under cardio-pulmonary bypass.
METHODSOne hundred and twenty patients undergoing valve replacement operation under cardio-pulmonary bypass were randomly divided into the SFI group and the control group, 60 in each group. Intravenous infusion of 1 ml/kg SFI was given to the SFI group, 30 min before anesthesia, and to the control group, equal volume of normal saline was given instead. The following indices were observed: (1) the hemodynamic changes occurred in the operational period; (2) the dosage of vaso-active drugs used during and after operation; (3) the post-operational recovery time of patients.
RESULTSThe mean arterial pressure and heart rate in the SFI group during operation were higher, while the central venous pressure was lower than those in the control group (P < 0.05). The dosage of vaso-active drugs, such as dopamine, dobutamine, sodium nitroprusside and lidocaine, used during and after operation was lower, and the extubation time and the intensive care unit (ICU) staying time were shorter in the SFI group when compared with those in the control group (P < 0.05).
CONCLUSIONSFI has certain protective effects on the cardiac function of patients undergoing valve replacement operation under cardio-pulmonary bypass.
